CORSEARCH
Corsearch, the leading provider of brand protection and trademark solutions, has today shared research forecasting that the number of active global trademarks will surpass the 100 million mark by 2026, in just two years.
Data from the Corsearch TrademarkNow platform shows that there were 83,613,385 active trademarks at the end of 2023, predicted to rise to 88,072,867 by the end of this year. Corsearch calculations forecast that by 2026, this figure will reach 100,720,928 – an increase of over 150% from the 2016 figures from a decade prior.
This growth in active trademark volumes demonstrates the increasing number of intellectual properties being developed and used by organizations across the world, in addition to a growing focus on the importance of protecting your intangible assets.
Examining 2024 filing figures, Corsearch can reveal that the country with the most active companies filing trademarks is China, followed swiftly by the USA and Brazil. The UK ranks 8th globally and, of the EU, only France features in the top ten most active filing countries.
Trademark volume rankings by originating country, 2023 |
|
1. |
China |
2. |
USA |
3. |
Brazil |
4. |
India |
5. |
Turkey |
6. |
Mexico |
7. |
Japan |
8. |
United Kingdom |
9. |
Russia |
10. |
France |
In order to support in-house counsel and expert IP advisors through this period of significant growth, Corsearch has also today announced its next-generation TrademarkNow platform. Lightning-fast AI and insights from 1,000+ sources ensure comprehensive trademark searching and monitoring – upgrades include:
- 75% faster turnaround time for notices than other industry solutions. Automated and Expert Watch solutions offer options between AI technology to deliver efficient monitoring of trademarks in the face of expanding trademark portfolios without sacrificing accuracy, or bespoke strategies and focused insights for more complex, high-value matters
- 40% improvement in IP legal team speeds of delivery for brand name clearance, with Corsearch LogoCheck and Name Generator tools allowing better searching of existing brand identities in combination with AI suggestions of candidate names
- Industrial Designs can be searched faster and more accurately through new similarity algorithms and the Corsearch AI image recognition engine
- ExaMatch search modifiers and NameCheck reporting allow for more targeted search queries and customizable reports better fit for individual needs
Viji Krishnan, President of Trademark Solutions, Corsearch, commented:
“Over the past years, the world has been waking up to the importance of trademarking intangible assets and intellectual property, and the risks of not doing so. It’s no surprise that we are only a few years away from seeing over 100 million trademarks active across the globe. It’s an optimistic sign of the intense innovation fuelling global organizations and empowering global business.
“But as with most things: the higher the volume of actively registered trademarks, the greater the potential complexity for IP professionals. We’re delighted to be launching our next-generation TrademarkNow platform to help experts in our sector cut through the noise. New AI tools will operate at the sheer scale needed to manage the size of modern trademark portfolios, effective dashboards which help prioritize work and the combined human expertise of our analysts who average over 15 years’ experience, ensures that brands uphold trademark distinctiveness.”
Notes to Editors
Methodology
Corsearch calculations are based on the data sourced from the TrademarkNow™ global trademark platform spanning all global trademark offices and registries. Where applicable, the effects of COVID on trademark filing have been accounted for.
About Corsearch:
Corsearch’s leading Trademark and Brand & Content Protection Solutions are revolutionizing how companies create, monitor, and protect their brands. Over 5,000 businesses worldwide partner with Corsearch to safeguard consumers and their trust in brands — preventing confusion, misrepresentation, and fraud using the hybrid intelligence of advanced AI precision and expert decision of human analysts.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521172877/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release
Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom